The trial will assess the safety and tolerability of ER‑100, an epigenetic restoration therapy designed to restore retinal ganglion cell function, while also measuring visual outcomes.
Resbiomed, a placental collagen materials manufacturer, is working on scaling up production for what appears regenerative ophthalmology in Europe.
OpCT-001 is an iPSC-derived cell therapy for retinitis pigmentosa, and it's now entering clinical testing following Orphan Drug status.
Celularity and DefEYE’s agreement aims to accelerate the development and commercialization of advanced regenerative biologic solutions for ophthalmic care.
Researchers are exploring whether SIRT1 gene therapy can protect human retinal cells from damage linked to optic neuropathies.
The trial will test whether lab-grown photoreceptor cells can be safely transplanted to help people with inherited vision loss.
The Bayer owned company just starting dosing patients with OpCT-001, an iPSC-derived cell therapy aiming to restore vision in inherited retinal diseases.
This milestone positions BlueRock Therapeutics to accelerate clinical development of OpCT-001, aiming to restore vision in patients facing irreversible blindness.
Luxa Biotechnology LLC has shared clinical data from its Phase 1/2a trial of RPESC-RPE-4W, a retinal pigment epithelium cell therapy for dry age-related macular degeneration (dry AMD). On the trial page, they...
Link to the study on Nature The problem? Visual disturbances caused by a deficiency of limbal epithelial stem cells (LESCs) in one eye, known as unilateral limbal stem cell deficiency (USCD). It's...
